BlackRock Health Sciences Trust(BME)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL RECENCY
3-STAR RATING
WEAK BUY
BUY for 83 days
PROFIT SINCE LAST BUY
+14.89% ▲
LAST CLOSE
$44.98
09/24/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for BME

09/24/2026: BME (3-star) is a REGULAR-BUY. BUY for 83 days. Simulated Profits (14.89%). Updated daily EoD!

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit 42.19%
Avg. Invested days 78
Today’s Advisory WEAK BUY
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 4.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/24/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BME receives a 3-star rating, supported by available scored pillars. The rating is constrained by soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
BME has moderate overall fundamentals (3 stars), with solid financial health, solid growth momentum, and soft ownership. In FY2025 versus FY2024, strong earnings growth (+228.2%) and strong revenue growth (+50.2%) are partially offset by soft cash generation (FCF margin -12.0%), very low insider ownership of 0.00%.

Financial Health Rating

★★★★★
BME's financial health is supported by strong profitability, including gross margin of 84.4% and operating margin of 212.9%. Liquidity is soft (2 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is BME's strongest growth driver at +228.2% FY2025 versus FY2024 (strong, 5 stars). By comparison, revenue growth (+50.2%, strong) is also strong, while free-cash-flow growth (-106.6%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 20.1% and approximately 0.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership is only 0.00%, which materially reduces the ownership score.

Unit Economics (Per $1K Revenue)

★★★★★
BME generates approximately $844 of gross profit, $2,129 of operating income, and $-120 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
BME has a high-quality, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedQuality TiltLow VolatilitySmall / Mid Cap Risk

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 581.46M USD
Price to earnings Ratio 5.58
1Y Target Price -
Price to earnings Ratio 5.58
1Y Target Price -
Volume (30-day avg) 39.9K shares
Beta 0.59
52 Weeks Range 33.36 - 46.16
Updated Date 09/24/2026
52 Weeks Range 33.36 - 46.16
Updated Date 09/24/2026
Dividends yield (FY) 6.99%
Basic EPS (TTM) 8
Advertisement

Valuation

Trailing PE 5.58
Forward PE -
Enterprise Value 577.36M
Price to Sales(TTM) 5.99
Enterprise Value 577.36M
Price to Sales(TTM) 5.99
Enterprise Value to Revenue 5.57
Enterprise Value to EBITDA -
Shares Outstanding 12.92M
Shares Floating -
Shares Outstanding 12.92M
Shares Floating -
Percent Insiders -
Percent Institutions 20.06

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About BlackRock Health Sciences Trust

Exchange NYSE
Headquarters New York, NY, United States
IPO Launch date 2005-03-29
CEO -
Sector Financial Services
Industry Asset Management
Full time employees -
Full time employees -

BlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.